A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Dose-Response Relationship, Drug, Drug Therapy, Combination, Zidovudine, HIV Protease Inhibitors, Ritonavir, Lamivudine, Anti-HIV Agents
Eligibility Criteria
Inclusion Criteria Children may be eligible for this study if they: Are HIV-positive. (Infants under 3 months old presumed to be HIV-positive are eligible to participate in the single-dose phase of the study.) Are between the ages of 4 weeks and 2 years (consent of parent or guardian required). Exclusion Criteria Children will not be eligible for this study if they: Have an opportunistic (AIDS-related) infection within 2 months of study entry. Are allergic to 3TC and/or ZDV. Have received anti-HIV drugs for 6 to 12 weeks. Have any infections requiring treatment. Are experiencing wasting (significant weight loss). Have any malignancies (cancer). Have certain immune diseases, are being fed through a tube, or have HIV-related encephalopathy (a degenerative disease of the brain).
Sites / Locations
- Long Beach Memorial Med. Ctr., Miller Children's Hosp.
- UCSD Maternal, Child, and Adolescent HIV CRS
- Howard Univ. Washington DC NICHD CRS
- Tulane/LSU Maternal/Child CRS
- HMS - Children's Hosp. Boston, Div. of Infectious Diseases
- NYU Med. Ctr., Dept. of Medicine
- Nyu Ny Nichd Crs
- Columbia IMPAACT CRS
- Incarnation Children's Ctr.
- Harlem Hosp. Ctr. NY NICHD CRS
- The Children's Hosp. of Philadelphia IMPAACT CRS
- St. Jude/UTHSC CRS